A Systematic Review of Systematic Reviews on the Use of Aromatase Inhibitors for the Treatment of Endometriosis: The Evidence to Date
Panagiotis Peitsidis,Panagiotis Tsikouras,Antonio Simone Laganà,Alexandros Laios,Ioannis D Gkegkes,Christos Iavazzo
DOI: https://doi.org/10.2147/DDDT.S315726
2023-05-04
Abstract:Panagiotis Peitsidis, 1 Panagiotis Tsikouras, 2 Antonio Simone Laganà, 3 Alexandros Laios, 4 Ioannis D Gkegkes, 5 Christos Iavazzo 6 1 Department of Obstetrics and Gynecology Helena Venizelou Hospital, Athens, Greece; 2 Department of Obstetrics and Gynecology.The Democritus University of Thrace, Alexandroupolis, Greece; 3 Unit of Gynecologic Oncology ARNAS "Civico-Di Cristina-Benfratelli", Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Palermo, Italy; 4 Department of Gynecological Oncology St James Institute of Oncology, Leeds Teaching Hospitals, Leeds, Uk; 5 Department of Colorectal Surgery, Royal Devon and Exeter NHS Foundation, Devon, UK; 6 Gynaecological Oncology Department, Metaxa Cancer Hospital, Piraeus, Greece Correspondence: Panagiotis Peitsidis, Department of Obstetrics and Gynecology, Helena Venizelou Hospital Athens Greece, Helena Venizelou 2 Street, P.C, Athens, 11521, Greece, Tel +306972221553 ; +302107473793, Email Endometriosis is a chronic gynecologic condition that affects around 6– 10% of reproductive age women. This clinical entity is characterized with pelvic pain, dysmenorrhea, dyspareunia, and infertility which are the most often presenting symptoms. Aromatase P450 is the key enzyme for ovarian estrogen biosynthesis and there is evidence that endometriotic lesions express aromatase and are able to synthesize their own estrogens. Aromatase inhibitors (AIs) are potent drugs that suppress the estrogen synthesis via suppression of aromatase. We performed a systematic review of systematic reviews and narrative reviews on the use of aromatase inhibitors in the medical management of endometriosis. We searched: PubMed (1950– 2022), Google Scholar (2004– 2022), Cochrane Library (2010– 2022) and Researchgate (2010– 2022). The search included the following medical subject headings (MeSH) or keywords: "Aromatase Inhibitors" AND "Endometriosis" AND "Systematic reviews" OR "Systematic review" AND "Reviews" OR "Reviews" AND "Endometriosis". The electronic database search yielded initially 12,106 studies from the different databases. Further assessment of the studies resulted in exclusion of (n = 12,015) studies due to duplicates and irrelevance; Finally, 24 studies were selected for inclusion, 5 were Systematic reviews and 19 were Narrative reviews. The 5 systematic reviews were assessed by AMSTAR-2 criteria and were found to have low quality. Narrative reviews were assessed with SANRA criteria and were found to have high-quality aromatase inhibitors are potent drugs that can manage the endometriosis-related symptoms in cases where initial medical management has failed to show positive results. However, their use is limited by the adverse effects that are linked with menopausal symptoms. aromatase inhibitors can be administered as an alternative treatment in patients. Future studies with randomized design are required to reach safer conclusions and further investigation. These studies should define the therapeutic dose, new add-back therapy modalities. Future directions should examine the most-appropriate way of administration and the duration of therapy. Keywords: endometriosis, aromatase inhibitors, systematic review, pelvic pain, adverse effects Endometriosis is a chronic gynecologic condition that affects around 6–10% of reproductive-age women. This clinical entity is characterized by pelvic pain, dysmenorrhea, dyspareunia, and infertility which are the most often presenting symptoms. The disease exhibits an estrogen-dependent growth of the endometrial glands and stroma outside the endometrial cavity. 1 Several risk factors of endometriosis have been reported, such as early menarche, short menstrual cycles, late menopause, low body mass index (BMI), nulliparity, increased consumption of alcohol, caffeine, and prolonged menstruation. 2 The most common theory of the pathogenesis of endometriosis is the theory of retrograde menstruation; however, retrograde menstruation occurs in nearly all women and not all women are afflicted with this condition. Hence, it has been postulated that women with endometriosis are likely to contain underlying molecular abnormalities that promote the continuous growth of endometrial tissues outside the uterine cavity. 3 Aromatase P450 is the key enzyme for ovarian estrogen biosynthesis. It catalyzes the conversion of androstenedione and testosterone produced in the ovarian theca cells to estrone and estradiol (E2) in the ovarian granulosa cells. Recently, there is evidence that demonstrates that endometriotic lesions express aromatase and can synthesize their own E2. 4 Aromatase inhibitors (AIs) Aromatase Inhibitors were first used for the treatment of -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal